Relay Therapeutics is trading 5.1% down at $18.63 following a pre-market pullback from its previous close of $19.63.
- The stock appears to be undergoing a technical reversal or pause after a recent rally fueled by positive analyst coverage, including an Overweight initiation from JPMorgan.
- There are no fresh company-specific catalysts, such as earnings reports, clinical trial updates, or FDA announcements, to account for the downward move.